These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 39371922)

  • 1. Glucagon-like peptide-1 receptor agonists in neoplastic diseases.
    Ji L; He X; Min X; Yang H; Wu W; Xu H; Chen J; Mei A
    Front Endocrinol (Lausanne); 2024; 15():1465881. PubMed ID: 39371922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.
    Scheen AJ
    Expert Opin Drug Saf; 2024 Jul; 23(7):797-810. PubMed ID: 38738549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Kintzoglanakis K; Diamantis C; Mariolis A; Paschou SA
    Diab Vasc Dis Res; 2024; 21(4):14791641241269743. PubMed ID: 39139128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists and kidney outcomes.
    MacIsaac RJ; Trevella P; Ekinci EI
    J Diabetes; 2024 Oct; 16(10):e13609. PubMed ID: 39364792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
    Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
    J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
    Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
    J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
    Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
    BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database.
    Kim TH; Lee K; Park S; Cho H; Park J; Jo H; Son Y; Kim S; Kang J; Smith L; Rahmati M; Fond G; Boyer L; Pizzol D; Lee H; Rhee SY; Hwang J; Sang H; Yon DK
    Diabetes Obes Metab; 2024 Nov; 26(11):5183-5191. PubMed ID: 39161072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.
    Wang L; Xu R; Kaelber DC; Berger NA
    JAMA Netw Open; 2024 Jul; 7(7):e2421305. PubMed ID: 38967919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality.
    Dicker D; Sagy YW; Ramot N; Battat E; Greenland P; Arbel R; Lavie G; Reges O
    JAMA Netw Open; 2024 Jun; 7(6):e2415392. PubMed ID: 38848064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
    Shaefer CF; Kushner P; Aguilar R
    Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
    Krishnan A; Schneider CV; Hadi Y; Mukherjee D; AlShehri B; Alqahtani SA
    Diabetologia; 2024 Mar; 67(3):483-493. PubMed ID: 38117293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Wong SY; Lee ARYB; Sia AHJ; Wo YJ; Teo YH; Teo YN; Syn NL; Ong CC; Teo LL; Yeo TC; Poh KK; Kong WK; Wong RC; Sia CH
    Cardiovasc Drugs Ther; 2024 Apr; 38(2):371-389. PubMed ID: 35819544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
    Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
    Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.